The video shows the Mishev&Marashi (M&M) SCS needle for suprachoroidal drug delivery. Drs. Lukan Mishev and Ameen Marashi demonstrate injection technique and their early results in cases of DME, posterior uveitis, RVO with CME, and pseudophakic CME.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
Purpose: To compare the results of trabeculectomy with subconjunctival Bevacizumab and 5-Fluorouracil (5-FU); with trabeculectomy with 5-Fluorouracil alone in the short term (i.e. 3 months).. Study Design: Prospective, interventional study. Place and Duration of Study: Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi, from 18th December 2013 till 16th August 2018.. Material and Methods: A total of 30 eyes (15 in each group) in patients above 40 years of age with primary glaucoma, underwent trabeculectomy with 5-Fluorouracil (5-FU) (50 mg/ml) applied for 5 minutes. At the end of surgery, sub-conjunctival Bevacizumab (Avastin® 2.5 mg in 0.1 ml) was injected in one group. The postoperative IOP, bleb configuration, and complications at 1 day, 1 week, 1 month, and then monthly for 3 months was observed for both groups.. Results: The mean pre-operative IOP in the 5-FU group was 30.6 ± 17.1 mm Hg compared to 28.9 ± 18.9 mm Hg in the 5-FU + Bevacizumab group. The mean IOP of the ...
Purpose: Scarring after glaucoma filtering surgery remains the most frequent cause for bleb failure. The aim of this study was to assess if the postoperative injection of bevacizumab reduces the number of postoperative subconjunctival 5-fluorouracil (5-FU) injections. Further, the effect of bevacizumab as an adjunct to 5-FU on the intraocular pressure (IOP) outcome, bleb morphology, postoperative medications, and complications was evaluated. Methods: Glaucoma patients (N = 61) who underwent trabeculectomy with mitomycin C were analyzed retrospectively (follow-up period of 25 ± 19 months). Surgery was performed exclusively by one experienced glaucoma specialist using a standardized technique. Patients in group 1 received subconjunctival applications of 5-FU postoperatively. Patients in group 2 received 5-FU and subconjunctival injection of bevacizumab. Results: Group 1 had 6.4 ± 3.3 (0-15) (mean ± standard deviation and range, respectively) 5-FU injections. Group 2 had 4.0 ± 2.8 (0-12) (mean ±
The Spanish firm Sylentis has developed a compound to treat diseases of the retina, such as age-related macular degeneration and diabetic retinopathy, which will be administered by ophthalmic drops instead of intraocular injections.
Ozurdex official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more.
The most common surgical technique for controlling the intraocular pressure in glaucoma patients is trabeculectomy.In this surgery, internal cavity of the eye is connected by a fistula like openings to subconjunctival space. The main cause of failure in trabeculectomy is excessive postoperative conjunctival scarring at the site of fistula, which is related to severity of conjunctival vascularization, tortuousity of vessel, and fibroblast migration and proliferation. At the time of surgery most surgeons use mitomycin C, which is an antimitotic and antifibrotic agent, to improve the results of the procedure. Although this agent is very effective, but is not without complication. The most significant and sight threatening complications are low intraocular pressure and endophthalmitis. Therefore investigations are going on to find a much safer and effective agents. Bevacizumab is a monoclonal antibody against vascular endothelial factor (VEGF). VEGF is an important vasculogenic and fibrogenic factor ...
Purpose: : Corneal scarring is largely due to proliferation and differentiation of corneal fibroblasts into myofibroblasts. The purpose of this study was to first examine the effects of sirolimus (an inhibitor of the mTOR pathway) on human corneal fibroblast proliferation and differentiation. Next, we wished to investigate the effect of sirolimus in preventing stromal haze formation after Photorefractive Keratectomy in a rabbit model. Methods: : Human corneal fibroblast cultures were initiated from donated human corneal tissue. After passages 3, the fibroblasts were treated with Sirolimus (1 μg/ml) + TGF-β (1 ng/ml) or TGF-β alone as control. Cell proliferation and expression of the myofibroblast marker alpha-smooth muscle actin (αSMA) were examined by phase-contrast microscopy and immunostaining. For in vivo studies, 140 micron PTK was performed on the right eye of 12 New Zealand White rabbits. Six eyes received 1mg subconjunctival sirolimus immediately and 2 weeks following the surgery. ...
Topical bevacizumab administration in clinical studies: 1% (10mg/ml) bevacizumab 4 times/day; 0,5% (5 mg/ml) bevacizumab for 0,5-12 months (5 times/day), 1% topical bevacizumab for 2-4 times/day for 3 weeks. Topical 5 mg/ml 4 times daily during 8 weeks can be used as reductive treatment for squamous neoplasia of conjunctiva and cornea. Subconjunctival bevacizumab application: 2,5 mg/0,1 ml; 3 injections of 2,5 mg/0,1 ml bevacizumab. Intrastromal application: 1-2 subconjunctival詻歪쭫ꉦ� injections (1,25 mg/0,05 mL) at 1-month intervals, deep intrastromal (2,5 mg/0,1 mL) bevacizumab after deep anterior keratoplasty; 27-gauge needle 2,5 mg/0,1 ml deep intrastromal paracentral injection ...
Described herein are devices and methods for treating eye conditions. Described is an ocular implant including an elongate member having an internal lumen forming a flow pathway, at least one inflow port communicating with the flow pathway, and at least one outflow port communicating with the flow pathway. The elongate member is adapted to be positioned in the eye such that at least one inflow port communicates with the anterior chamber, at least one outflow port communicates with the suprachoroidal space to provide a fluid pathway between the anterior chamber and the suprachoroidal space when the elongate member is implanted in the eye. The elongate member has a wall material imparting a stiffness to the elongate member. The stiffness is selected such that after implantation the elongate member deforms eye tissue surrounding the suprachoroidal space forming a tented volume.
Eye diseases such as uveitis and diabetic macular edema present in the choroid and retina. Through the ingenious efforts of our research and development team, we have developed a unique and elegant way to access the choroid and retina through the suprachoroidal space to treat these diseases.. PIPELINE. ...
Viscoat - Get up-to-date information on Viscoat side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about Viscoat
Ozurdex with NDC 0023-3348 is a a human prescription drug product labeled by Allergan, Inc.. The generic name of Ozurdex is dexamethasone.
PURPOSE To report the outcomes of corneal fine needle diathermy (FND) with adjuvant intrastromal and subconjunctival bevacizumab injection for corneal neovascularization (CN) in children. METHODS Medical records of all children who had undergone FND with adjuvant bevacizumab injection were reviewed retrospectively. Treatment efficacy was evaluated by changes in visual acuity, regression of CN, and clearing of lipid deposits with the aid of slit-lamp color images that were taken before surgical intervention and at last follow-up visit. Postoperative complications were recorded and served to assess the safety of the procedure. RESULTS Nine eyes of 9 patients were included in the study. The mean age of the patients was 8.4 ± 4.2 years (4-15 years) and the mean follow-up time was 18.7 ± 12.2 months (5-35 months). Three eyes had a history of herpes simplex keratitis (HSK), 3 eyes had complete corneal anesthesia, 2 eyes had CN following suture tract infection after corneal transplant for HSK scar and
At that point our review of the literature indicated poor response of iatrogenic CNVM to laser photocoagulation, photodynamic therapy, and surgical removal of subretinal fluid.(2-6) Because intravitreal bevacizumab injections had been used effectively to treat CNVM secondary to other retinal diseases, it was decided that this treatment would be used in the present case. However, intravitreal bevacizumab injections are not readily available in our hospital, and strict criteria are applied before approval of their use. Treatment was started 5 weeks after the diagnosis of CNVM. Intravitreal bevacizumab injections in the right eye were administered every 6 weeks over a 6-month period, but visual acuity failed to improve. Nine months following surgery, a disciform scar developed and treatment was discontinued, at which time visual acuity in the right eye was counting fingers ...
The study demonstrated no difference in BCVA between the combination and MLT treatment arms at 56 weeks despite two mandated Ozurdex doses at 0 and 16 weeks and low threshold re-treatment criteria accounting for a mean of 3.5 Ozurdex injections in the combination arm. This result was unexpected in view of the visual gains experienced by patients after Ozurdex therapy in both the MEAD and PLACID studies between 4 and 12-week time-points, and there may be several explanations. First, it is possible that frequent dosing with Ozurdex does not provide additional visual function benefit compared with the less frequent dosing performed in MEAD and PLACID studies. However, the steady reduction in CST over the period of 56 weeks within OZLASE which differs to the rise and trough effect on CST noted in the MEAD and PLACID studies argues against this. The lack of correlation between this anatomical improvement and the visual outcome suggests that the latter has been confounded by the development and ...
With the development of new the technology researchers are able to use a hollow micron-scale needle to inject therapeutics into the suprachoroidal space located between the outer surface of the eye known as the sclera and the choroid which is a deeper layer providing nutrients to the rest of the eye. Preclinical research has demonstrated that fluid can flow between the two layers where it can spread out to the entire eye, including to the retina that is difficult to reach ...
US FDA has approved OZURDEX 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.
TY - JOUR. T1 - Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis. T2 - Primary 6-month results of the SAVE Study. AU - Nguyen, Quan Dong. AU - Ibrahim, Mohamed A.. AU - Watters, Anthony. AU - Bittencourt, Millena. AU - Yohannan, Jithin. AU - Sepah, Yasir J.. AU - Dunn, James P.. AU - Naor, Joel. AU - Shams, Naveed. AU - Shaikh, Ovais. AU - Leder, Henry Alexander. AU - Do, Diana V.. PY - 2013/12/1. Y1 - 2013/12/1. N2 - Background: The purpose of this study is to evaluate the ocular tolerability and efficacy of sirolimus administered as subconjunctival or intravitreal injections in patients with non-infectious uveitis. Sirolimus as a Therapeutic Approach for Uveitis (SAVE) is a prospective, randomized, open-label, interventional study. Thirty patients were enrolled and randomized in 1:1 ratio to receive either intravitreal injections of 352 μg sirolimus or subconjunctival injections of 1,320 μg at days 0, 60, and ...
Introduction Hydrogen sulfide (H2S) therapy is recognized as a modulator of vascular function during tissue ischemia. Although the nitric oxide synthase (NOS) dependent mechanisms of H2S mediated protection during chronic tissue ischemia is slightly known but NOS independent nitrite reduction mechanism is still unknown. Hypothesis To determine NOS independent molecular mechanism involved in H2S regulation of NO metabolism and the importance of these effects during chronic tissue ischemia. Methods: Left femoral artery ligation and excision were done in wild type and eNOSKO mice (n=8, each group). PBS, 0.1, 0.5 and 1mg/kg sodium sulfide (Na2S) was administered twice daily by retro-orbital injection. Hind limb perfusion was measured using a laser Doppler perfusion probe. Angiogenic and cell proliferation index were determined by the ratio of CD31 to DAPI and Ki67/ DAPI positive staining respectively. NO generation by Na2S and nitrite interaction in the presence of xanthine oxidase (XO) in ...
TY - JOUR. T1 - Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. AU - Nomoto, Hiroyuki. AU - Shiraga, Fumio. AU - Kuno, Noriyuki. AU - Kimura, Erika. AU - Fujii, Shinobu. AU - Shinomiya, Katsuhiko. AU - Nugent, Alex K.. AU - Hirooka, Kazuyuki. AU - Baba, Tetsuya. PY - 2009. Y1 - 2009. N2 - PURPOSE. To investigate the pharmacokinetics of bevacizumab in rabbits for three different routes of administrations: intravitreal injection, subconjunctival injection, and eye drops. METHODS. Pigmented rabbits received bevacizumab in one eye by topical eye drops (1.25 mg/0.05 mL six times daily for the first 7 days), single subconjunctival injection (1.25 mg/0.05 mL), or single intravitreal injection (1.25 mg/0.05 mL). Bevacizumab concentrations in plasma and ocular tissues in the treated and fellow eyes were determined by sandwich enzymelinked immunosorbent assay at 1, 2, 4, and 12 weeks after administration. RESULTS. After intravitreal injection in ...
2013 (English)In: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 91, no 2, e154-e154 p.Article in journal, Letter (Refereed) Published ...
More recently, our groups, the Bionics Institute and the Centre for Eye Research Australia, working as part of the Bionic Vision Australia (BVA) partnership, ran a series of preclinical studies between 2009 and 2012.4 These studies demonstrated the safety and efficacy of a prototype suprachoroidal implant, made up of a silicone carrier with 33 platinum disc-shaped electrodes that can be activated in various combinations to elicit the perception of rudimentary patterns, much like pixels on a screen. Two years ago, BVA commenced a pilot trial, in which researchers implanted the prototype in the suprachoroidal space of three end-stage retinitis pigmentosa patients who were barely able to perceive light. The electrode array was joined to a titanium connector affixed to the skull behind the ear, permitting neurostimulation and electrode monitoring without the need for any implanted electronics.5 In all three patients, the device proved stable and effective, providing enough visual perception to ...
The researchers used microneedles less than a millimeter in length to inject a fluorescent dye, a drug (bevacizumab) and small polymer particles into the suprachoroidal space in rabbits eyes. This is just behind the sclera (the white part of the eye) and allows drug to flow along the inner surface of the eye to the back, including the retina. ...
Causes of Subconjunctival hemorrhage including triggers, hidden medical causes of Subconjunctival hemorrhage, risk factors, and what causes Subconjunctival hemorrhage.
Deksametazon, intravitrealni implantat v aplikatorju, ATC S01BA01, SmPC (Povzetek glavnih značilnosti zdravila) Indikacije: Zdravilo OZURDEX je indicirano za zdravljenje odraslih bolnikov z: okvaro vida zaradi diabetičnega makularnega edema (DME), ki imajo psevdofakijo ali se slabše odzivajo ali niso primerni za zdravljenje brez kortikosteroidov; makularnim edemom po okluziji veje retinalne vene (BRVO-Branch Retinal Vein Occlusion) ali okluziji centralne retinalne vene (CRVO-Central Retinal V...
Need Viscosurgical Devices & other medical supplies? Head to Medex Supply and check out the Alcon Ophthalmic Viscosurgical Device, Viscoat, 0.5 mL
In the last EdgeBlast issue, we reported that HCPCS Level II codes for the H1N1 vaccine and Bevacizumab injection were recently added to the Medicare Physi
Usually, treatment is unnecessary. A subconjunctival hemorrhage will resolve on its own. Your doctor may recommend that you use artificial tears several …. Subconjunctival hemorrhage is a broken blood vessel in the eye - Learn more about this common, harmless condition that clears up without treatment.. Subconjunctival Hemorrhage Overview. The conjunctiva is the thin, moist, transparent membrane that covers the white part of the eye (called the sclera) and …. Amaryl Diabetes Side Effects Metformin Side Effects: An Introduction As with any medicine, there are possible side effects with metformin (Glucophage ®) or metformin ER (Glucophage XR® Amaryl (glimepiride) is a prescription drug used to control. What causes a subconjunctival hemorrhage? … The conjunctiva contains nerves and many small blood vessels. These blood vessels are usually barely visible …. Most of the time, no symptoms are associated with a subconjunctival hemorrhage other than seeing blood over the white part of the eye. ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Find the best subconjunctival hemorrhage doctors in Bangalore. Get guidance from medical experts to select subconjunctival hemorrhage specialist in Bangalore from trusted hospitals - credihealth.com
A subconjunctival haemorrhage is one cause of a red eye. It is caused by a small bleed behind the conjunctiva. About Subconjunctival Haemorrhage
The conjunctiva is a relatively loose structure and any bleeding can easily spread and appear quite alarming. Patients are, however, often asymptomatic and may only become aware of having a red eye when looking in the mirror or having it pointed out to them.. The majority of subconjunctival haemorrhages occur spontaneously without an identifiable cause, the patient occasionally complaining of a sudden "popping" feeling in the eye. It is likely that many of these patients may have had mild trauma eg eye rubbing, which has contributed to the bleed.. ...
A subconjunctival hemorrhage is when a blood vessel breaks open in the white of the eye. It causes a bright red patch in the white of the eye. It is similar to a bruise on the skin.
That is the word for the day. Actually Subconjunctival hemorrhage is my word of the month! Had to go thru this twice in a row last week. I have to keep a close eye on my food intakes since I read that there are a lot of factors that might cause the blood vessels in my eyes to burst like that and goes away in about 1 week ...
https://doi.org/10.18632/oncotarget.3493 Shuai Liu, Bing Han, Qunyuan Zhang, Jie Dou, Fang Wang, Wenli Lin, Yuping Sun, Guangyong Peng
Purpose : To evaluate the short-term variation of central macular thickness (CMT) after intravitreal bevacizumab injection for diabetic macular edema. Methods : A prospective observational clinical study was performed. Written informed consent was obtained for every patient. Study was approved by the Ethics Committee number 35463914.2.0000.0088. Trial was registered at EudraCT number 2015-005516-15. Assessment for best corrected visual acuity (BCVA) was performed at baseline and 24 hours, 3 days, 7 days, 14 days, 21 days, and 28 days after intravitreal injection of bevacizumab. Complete ophthalmic examination including fundus biomicroscopy and optical coherence tomography central macular thickness using Spectralis (Heidelberg Engineering) were performed at baseline and 1 hour, 4 hours, 24 hours, 3 days, 7 days, 14 days, 21 days, and 28 days after intravitreal injection of bevacizumab. Results : A total of 16 eyes of 12 patients (6 male; mean age, 62 ± 8.7 years; range, 50-74 years) who ...
Even though a subconjunctival hemorrhage can be a benign finding, there are many conditions that can cause hemorrhages that deserve investigation. If youve had a recent trauma, you definitely need to see a doctor in case there is an open abrasion or maybe even a deeper injury that needs treatment. Blood pressure should be checked when a subconjunctival hemorrhage appears without history of trauma - a study of 78 patients with spontaneous presentation of subconjunctival hemorrhage (average age 53) showed that 46% of patients with subconjunctival hemorrhage had elevated blood pressure. If you have recurrent subconjunctival hemorrhages, having blood work done to test for dangerous systemic conditions is a good idea. In addition to checking blood pressure and blood sugar, your doctor may order blood work to rule out anemia, leukemia, and blood clotting disorders like polycythemia. Most of the time subconjunctival hemorrhages are just an annoyance, but they can be a sign of a deeper health problem ...
The suprachoroidal space is normally virtual because the choroid is in close apposition to the sclera. As fluid accumulates, this space becomes real, and the choroid is displaced from its normal position.
Learn about Ozurdex (Dexamethasone Intravitreal Implant) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
A subconjunctival hemorrhage is similar to an ordinary bruise on the skin - its like a bruise of the eye. It usually appears as a single, concentrated spot of
Subconjunctival Hemorrhage in Monaca, PA. OPTOMETRIC CARE INC is your local Optometrist in Monaca serving all of your needs. Call us today at (724) 774-7232 for an appointment.
Bloodshot eyes arent exactly the best feature of a person! When a persons eyes are bloodshot, it is quite easy to see that something is wrong! ...
[ChEMBL Compound Description] ID:, InChI_Key:, Tradenames:Aeroseb-dex | Dexone 4 | MAXIDEX | OZURDEX | Decaderm | Decaspray | Dexamethasone | Dexone 0.75 | Dexone 1.5 | Kortico Injection | DECADRON | Dexone 0.5 | Dexamethasone intensol | DEXONE | Dalalone | HEXADROL, Synonyms:DEXAMETHASONE METASULFOBENZOATE SODIUM | Dalalone | OZURDEX | Dexacen-4 | Decaderm | MAXIDEX | Dexone 4 | Aeroseb-dex | HEXADROL | DEXAMETHASONE | DEXAMETHASONE PALMITATE | Dexamethasone intensol | DECADRON | DEXAMETHASONE VALERATE | Dexone 0.5 | FLUORMETHYLPREDNISOLONE | Decadron-LA | Mymethasone | Dexacort | Decaspray | Kortico Injection | Dexone 1.5 | Dexone 0.75 | DEXONE | Neodecadron | Dexair
We describe the case of a man who died of an abdominal aortic aneurysm rupture after an intravitreal injection of bevacizumab for neovascular age-related macular degeneration. A 74-year-old Korean man presented with visual disturbance in his right eye. He had previously been diagnosed with diabetes and hypertension, which were controlled with oral medications. We diagnosed him with neovascular age-related macular degeneration and he was treated by monthly intravitreal injection of bevacizumab for three months. Four days after his third intravitreal bevacizumab injection, he died of an abdominal aortic aneurysm rupture and uncontrolled bleeding. Abdominal aortic aneurysm rupture is highly lethal and there is a possible correlation with intravitreal injection of bevacizumab. Thus, we need to consider the risks of intravitreal bevacizumab injections for patients with abdominal aortic aneurysms.
TY - JOUR. T1 - Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. AU - Gilger, Brian C.. AU - Wilkie, David A.. AU - Clode, Allison B.. AU - McMullen, Richard J.. AU - Utter, Mary. AU - Komaromy, Andras M.. AU - Brooks, Dennis E.. AU - Salmon, Jacklin H.. PY - 2010/9/1. Y1 - 2010/9/1. N2 - Objective: To determine the long-term efficacy, complications, and duration of effect of a cyclosporine (CsA) suprachoroidal implant (CSI) in horses with equine recurrent uveitis (ERU). Methods: Horses with ERU were treated with a 6-mm diameter, 25 mg, reservoir matrix CsA implant in the deep sclera adjacent to the suprachoroidal space. Horses with follow-up ,1 year were examined for frequency of uveitis episodes, complications, and vision at last recheck. Results: Data from 151 eyes of 133 horses from the USA and Europe that had CsA devices implanted for ERU were reviewed. Follow-up time ranged from 13 to 85 months after surgery, with ...
PURPOSE: To assess aqueous humor lidocaine concentrations in 2 common regimens of topical anesthesia and after intracameral injection of the anesthetic agent. SETTING: University hospital eye clinic. METHODS: Twenty patients having routine cataract surgery were randomized into 3 groups: 1 given 3 drops of lidocaine 4% before surgery; 1 given 6 drops; 1 given 3 drops plus an intracameral injection of 0.1 mL lidocaine 1%. Lidocaine concentration was measured in aqueous humor samples taken before surgery. RESULTS: With 3 drops, aqueous lidocaine concentration was 1.4 micrograms/mL +/- 0.5 (SD) and with 6 drops, 4.3 +/- 1.5 micrograms/mL (P = .0015). With an intracameral injection, it was 341.8 +/- 152.6 micrograms/mL. CONCLUSION: Measurable amounts of lidocaine entered the anterior chamber in topical anesthesia, and more entered when more drops were given. It is likely that concentrations in this range could anesthetize the iris, but they are far lower than concentrations after an intracameral ...
Please read the general principles page before attempting any blood sampling procedure. Technique Summary Resources and references Retro-orbital technique in other animals All blood sampling techniques in the mouse Technique Also referred to as peri-orbital, posterior-orbital and orbital venous sinus bleeding. Retro-orbital bleeding should be performed as a terminal procedure. It should only be used with recovery in rare circumstances with exceptional scientific justification (e.g. where a large blood volume is necessary or where peripheral veins are used for dosing), because of its potential impact on animal welfare. Adverse effects reported for this procedure are described in the summary below. Where its use is unavoidable, retro-orbital bleeding should only be used under terminal or general anaesthesia. Because of the severity of the adverse effects that can occur with this technique, even in skilled hands, it is essential that it is conducted only by staff members competent (practised) in the
To investigate the effect of intravitreal bevacizumab and ranibizumab on wound tension and by histopathology during cutaneous wound healing in a rabbit model and to compare this effect to placebo intravitreal saline controls 1 and 2 weeks following i
This case presented a therapeutic challenge due to bilateral vein occlusions concurrently with pregnancy precluding use of anti-VEGF agents. Anti-VEGF agents would be considered first line in this instance due to phakic status and treated primary angle closure had the patient not been pregnant. Available anti-VEGF agents are not recommended for use in pregnancy due to animal studies demonstrating harm. The USA Food and Drug Administration (FDA) classifies them as category C which they define as Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. It is interesting to note that were her visual loss secondary to diabetic macular oedema NICE guidance would not allow use of Ozurdex® due to her phakic status; a restriction not imposed on macular oedema secondary to vein occlusions. In conclusion we report an unusual case of ...